integrated global life science group lead out of it’s corporate offices in Switzerland. Our passion is creating groundbreaking health products. By using unique bioactive compounds extracted from
nature, we pioneer in tackling some of the world’s big challenges like obesity, antibiotic resistance and livestock emissions. Our teams are united by the desire to use our visionary biotech
innovations to help shape a better future for as many people in the world as possible.
With over €660m in
assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth
potential in two fields : Digital technologies in France and Germany, and Life sciences across Europe and North America.
In Life sciences, the
four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized
medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Recently, Seventure Partners successfully launched Health for Life Capital™
which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial
Seventure is a
subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.
details: www.seventure.com / Twitter @SeventureP
Pontifax is a venture
capital firm focusing on groundbreaking innovations in the life sciences arena. Founded in 2004 and with $350M under management, Pontifax seeks transformative, innovative healthcare opportunities at
all development stages.
NCI is an investment
company operating in Normandy and in Ile de France. For more than 15 years, NCI has been investing skilled resources and equity capital in the creation, the development and the transfer of companies.
With a double-digit growth track record, and about €200M under management (entrusted by public and private institutional investors), NCI strives to create sustainable value within its portfolio
companies by reconciling finance, economic development and social welfare.
For more details